Announcements
- eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
- eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
- eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
- eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
- eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
- eFFECTOR Therapeutics Announces Reverse Stock Split
More ▼
Key statistics
On Friday, eFFECTOR Therapeutics Inc (LWK:BER) closed at 1.53, 10.87% above the 52 week low of 1.38 set on May 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.57 |
---|---|
High | 1.59 |
Low | 1.42 |
Bid | 1.45 |
Offer | 1.50 |
Previous close | 1.57 |
Average volume | 30.00 |
---|---|
Shares outstanding | 4.70m |
Free float | 4.57m |
P/E (TTM) | -- |
Market cap | 7.53m USD |
EPS (TTM) | -13.31 USD |
Data delayed at least 15 minutes, as of May 31 2024 19:21 BST.
More ▼